Shares of Concordia International Corp (NASDAQ:CXRX) ended Friday session in green amid volatile trading. The shares closed up +0.40 points or 8.11% at $5.33 with 1.58 million shares getting traded. Post opening the session at $4.98, the shares hit an intraday low of $4.89 and an intraday high of $5.49 and the price vacillated in this range throughout the day. The company has a market cap of $251.51 million.
Concordia International Corp (CXRX) owns a portfolio of branded and generic prescription products in the United States and internationally. The companys Concordia North America segment has product right sales of pharmaceutical products primarily in the United States. This segment offers a portfolio of branded and generic products, including Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; and Plaquenil for the treatment of lupus and rheumatoid arthritis.
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) ended Friday session in red amid volatile trading. The shares closed down -0.31 points or 2.50% at $12.09 with 1.57 million shares getting traded. Post opening the session at $12.38, the shares hit an intraday low of $12.07 and an intraday high of $12.47 and the price vacillated in this range throughout the day. The company has a market cap of $1.53 billion and the numbers of outstanding shares have been calculated to be 129.41 million shares.
Halozyme Therapeutics, Inc. (HALO) on Sept. 1, 2016 named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer.
Gergen will be responsible for corporate development, including the management of Halozyme’s proprietary ENHANZE™ platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme’s oncology pipeline, including clinical operations and clinical collaborations.
“Mark brings a wealth of business development and operational experience that will be essential as we execute our plan to accelerate growth of the ENHANZE platform and develop and commercialize multiple oncology drugs,” said Dr. Torley. “With more than 20 years of healthcare and biotech experience, he will be a strong addition to our management team as we execute our growth strategy.”
Gergen joins Halozyme most recently from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer reporting to the CEO and responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions. He executed multiple successful partnerships, collaborations and licensing agreements.
Before Mirati, he spent 7 years at Amylin Pharmaceuticals as a member of the executive committee reporting to the CEO, where he led corporate development and alliances.
“I am excited to join the Halozyme team as the company continues to execute against its business objectives and corporate strategy,” said Gergen. “The advancements in the oncology pipeline together with the opportunity to grow the proprietary ENHANZE platform create a unique opportunity to build significant shareholder value.”